Model‐based assessments of CYP3A‐mediated drug‐drug interaction risk of milademetan

Milademetan is a small‐molecule inhibitor of murine double minute 2 (MDM2) that is in clinical development for advanced solid tumors and hematological cancers, including liposarcoma and acute myeloid leukemia. Milademetan is a CYP3A and P‐glycoprotein substrate and moderate CYP3A inhibitor. The curr...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Ying, Ishizuka, Tomoko, Watanabe, Akiko, Tachibana, Masaya, Lee, Mark, Ishizuka, Hitoshi, LaCreta, Frank, Abutarif, Malaz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604211/
https://www.ncbi.nlm.nih.gov/pubmed/34080309
http://dx.doi.org/10.1111/cts.13082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604211/
https://www.ncbi.nlm.nih.gov/pubmed/34080309
http://dx.doi.org/10.1111/cts.13082

Ejemplares similares